FIELD: pharmacology.
SUBSTANCE: invention refers to pharmacology and concerns an agent relieving postinfarction myocardial remodeling.
EFFECT: agent represents 4-methyl-2,6-diisobornylphenol, which in course introduction weakens postinfarction myocardial remodeling, reducing the area of involved myocardium and reducing the degree of left ventricular dilation.
1 cl, 2 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-ISCHEMIC DRUG | 2012 |
|
RU2499593C1 |
AGENT POSSESSING NEUROPROTECTIVE ACTIVITY | 2018 |
|
RU2701739C1 |
AGENT POSSESSING ENDOTHELIUM PROTECTIVE ACTIVITY | 2014 |
|
RU2563622C1 |
MEANS FOR CEREBRAL BLOOD FLOW INCREASE | 2016 |
|
RU2655810C2 |
AGENT WITH CARDIOPROTECTIVE ACTIVITY | 2019 |
|
RU2791641C2 |
HYDROPHILIC CONJUGATE OF HYDROXYETHYL STARCH AND 2,6-DIISOBORNYL-4-METHYLPHENOL | 2012 |
|
RU2497828C1 |
NOVEL DERIVATIVES OF 2,6-DI-ISOBORNYL PHENOL AND METHOD OF OBTAINING THEREOF | 2012 |
|
RU2516699C2 |
AGENT HAVING CARDIOPROTECTIVE ACTION AND 1,3-DISUBSTITUTED 2-AMINOBENZIMIDAZOLIUM HALIDES | 2013 |
|
RU2526902C1 |
ANTIISHEMIC AGENT | 2008 |
|
RU2384327C1 |
METHOD OF PREDICTING RIGHT VENTRICLE PARAMETRES AFTER SURGICAL CORRECTION OF VALVULAR DEFECT | 2008 |
|
RU2372033C1 |
Authors
Dates
2021-01-21—Published
2020-07-06—Filed